Severe eosinophilic is effectively treated with benralizumab, with especially good outcomes in patients with high BEC and high FeNO.
Mepolizumab reduces asthma exacerbations among real-world patients with severe asthma and an eosinophilic phenotype.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback